サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1609599

抗凝固薬中和剤の市場規模、シェア、動向分析レポート：製品タイプ別、流通チャネル別、地域別、セグメント別予測、2025年～2030年

Anticoagulant Reversal Drugs Market Size, Share & Trends Analysis Report By Product Type (Andexanet Alfa, Idarucizumab, Phytonadione (Vitamin K)), By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030

出版日
ページ情報
英文 100 Pages
納期
2～10営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.99円
抗凝固薬中和剤の市場規模、シェア、動向分析レポート：製品タイプ別、流通チャネル別、地域別、セグメント別予測、2025年～2030年
出版日: 2024年11月07日
発行: Grand View Research
ページ情報: 英文 100 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

抗凝固薬中和剤市場の成長と動向：

Grand View Research社の最新レポートによると、世界の抗凝固薬中和剤市場規模は2030年までに27億8,000万米ドルに達する見込みです。

2025年から2030年までのCAGRは12.3%で拡大する見込みです。出血性疾患の増加、新薬のイントロダクション、抗凝固療法を必要とする症例の増加は、予測期間中の市場成長を促進すると予想される要因の一部です。

2015年10月、ベーリンガーインゲルハイム製薬のPraxbind（イダルシズマブ）は、緊急手術時や制御不能または生命を脅かす出血時にプラザキサ（ダビガトラン）で治療された患者に適応される抗凝固薬中和剤として承認されました。従って、このような抗凝固薬中和剤が入手可能になったことで、医師や患者はより確信を持ってこのような治療法を検討できるようになり、抗凝固薬中和剤の需要が高まっています。

血友病のような出血性疾患は、後天性のものと遺伝性のものがあります。しかし、その他の出血性疾患は、HIV、貧血、白血病、肝硬変、ビタミンK欠乏症などの疾患によって発症する可能性があります。国立心肺血液研究所によると、米国では300万人以上が貧血に罹患しており、これは最も一般的な血液疾患です。白血病リンパ腫協会（LLS）は、2020年に白血病と診断されると予想される人の数は約60,530人であると述べています。出血性疾患の増加は抗凝固剤の需要を増加させ、市場の成長に拍車をかけています。

しかし、これらの抗凝固療法は高価であるため、市場の成長は抑制されると予想されます。米国心臓病学会（American College of Cardiology）によると、4-F PCC（Kcentra）はリバーロキサバンやアピキサバンによる出血症例の治療に役立ち、50単位/kgで投与されます。その平均卸売価格は1単位あたり2.90米ドルであるため、体重100kgの患者の治療には約1万4,500米ドルが必要となります。

抗凝固薬中和剤市場レポートハイライト：

  • イダルシズマブ（idarucizumab）セグメントは2024年に36.8%の売上シェアを占め、市場を独占しました。
  • 病院薬局が2024年の売上高シェアで48.6%と最も大きく、市場を独占しています。
  • 北米の抗凝固薬中和剤市場は2024年に38.6％の売上シェアで世界市場を独占しました。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 抗凝固薬中和剤市場の変数、動向、範囲

  • 市場系統の見通し
  • 市場力学
    • 市場 促進要因分析
    • 市場抑制要因分析
  • ビジネス環境分析
    • 業界分析- ポーターのファイブフォース分析
    • PESTLE分析

第4章 抗凝固薬中和剤市場：製品タイプ別ビジネス分析

  • 製品タイプ市場シェア、2024年および2030年
  • 製品タイプセグメントダッシュボード
  • 市場規模と予測および動向分析、製品タイプ別、2018年から2030年
  • プロトロンビン複合体濃縮物
  • フィトナジオン（ビタミンK）
  • アンデキサネットアルファ
  • イダルシズマブ
  • プロタミン
  • その他

第5章 抗凝固薬中和剤市場：流通チャネル別ビジネス分析

  • 流通チャネル市場シェア、2024年および2030年
  • 流通チャネルセグメントダッシュボード
  • 市場規模と予測および動向分析、流通チャネル別、2018～2030年
  • 病院薬局
  • 小売薬局
  • オンライン薬局

第6章 抗凝固薬中和剤市場：地域推定・動向分析と製品タイプの動向分析

  • 地域別市場シェア分析、2024年および2030年
  • 地域市場ダッシュボード
  • 市場規模、予測動向分析、2018年から2030年：
  • 北米
    • 国別、2018年-2030年
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • 国別、2018年-2030年
    • 英国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • ノルウェー
    • デンマーク
    • スウェーデン
  • アジア太平洋
    • 日本
    • 中国
    • インド
    • 韓国
    • オーストラリア
    • タイ
  • ラテンアメリカ
    • 国別、2018年-2030年
    • ブラジル
    • アルゼンチン
  • 中東・アフリカ
    • 国別、2018年-2030年
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • クウェート

第7章 抗凝固薬中和剤市場：流通チャネル別の地域別推定・動向分析

  • 地域別市場シェア分析、2024年および2030年
  • 地域市場ダッシュボード
  • 市場規模、予測動向分析、2018年から2030年：
  • 北米
    • 国別、2018年-2030年
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • 国別、2018年-2030年
    • 英国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • ノルウェー
    • デンマーク
    • スウェーデン
  • アジア太平洋
    • 日本
    • 中国
    • インド
    • 韓国
    • オーストラリア
    • タイ
  • ラテンアメリカ
    • 国別、2018年-2030年
    • ブラジル
    • アルゼンチン
  • 中東・アフリカ
    • 国別、2018年-2030年
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • クウェート

第8章 競合情勢

  • 参入企業概要
  • 企業の市況分析
  • 企業分類
  • 戦略マッピング
  • 企業プロファイル/リスト
    • Pfizer Inc
    • AstraZeneca
    • Dr. Reddy's Laboratories Ltd
    • Endo International plc
    • Teva Pharmaceutical Industries Ltd
    • Sun Pharmaceutical Industries Ltd
    • Mylan NV
    • Novartis AG.
    • Lupin
    • Cipla Inc
図表

List of Tables

  • Table 1. List of secondary sources
  • Table 2. List of abbreviations
  • Table 3. Global anticoagulant reversal drugs market, by region, 2018 - 2030 (USD Million)
  • Table 4. Global anticoagulant reversal drugs market, by product type, 2018 - 2030 (USD Million)
  • Table 5. Global anticoagulant reversal drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 6. North America anticoagulant reversal drugs market, by country, 2018 - 2030 (USD Million)
  • Table 7. North America anticoagulant reversal drugs market, by product type, 2018 - 2030 (USD Million)
  • Table 8. North America anticoagulant reversal drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 9. U.S. anticoagulant reversal drugs market, by product type, 2018 - 2030 (USD Million)
  • Table 10. U.S. anticoagulant reversal drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 11. Canada anticoagulant reversal drugs market, by product type, 2018 - 2030 (USD Million)
  • Table 12. Canada anticoagulant reversal drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 13. Mexico anticoagulant reversal drugs market, by product type, 2018 - 2030 (USD Million)
  • Table 14. Mexico anticoagulant reversal drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 15. Europe anticoagulant reversal drugs market, by country, 2018 - 2030 (USD Million)
  • Table 16. Europe anticoagulant reversal drugs market, by product type, 2018 - 2030 (USD Million)
  • Table 17. Europe anticoagulant reversal drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 18. UK anticoagulant reversal drugs market, by product type, 2018 - 2030 (USD Million)
  • Table 19. UK anticoagulant reversal drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 20. Germany anticoagulant reversal drugs market, by product type, 2018 - 2030 (USD Million)
  • Table 21. Germany anticoagulant reversal drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 22. France anticoagulant reversal drugs market, by product type, 2018 - 2030 (USD Million)
  • Table 23. France anticoagulant reversal drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 24. Italy anticoagulant reversal drugs market, by product type, 2018 - 2030 (USD Million)
  • Table 25. Italy anticoagulant reversal drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 26. Spain anticoagulant reversal drugs market, by product type, 2018 - 2030 (USD Million)
  • Table 27. Spain anticoagulant reversal drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 28. Norway anticoagulant reversal drugs market, by product type, 2018 - 2030 (USD Million)
  • Table 29. Norway anticoagulant reversal drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 30. Denmark anticoagulant reversal drugs market, by product type, 2018 - 2030 (USD Million)
  • Table 31. Denmark anticoagulant reversal drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 32. Sweden anticoagulant reversal drugs market, by product type, 2018 - 2030 (USD Million)
  • Table 33. Sweden anticoagulant reversal drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 34. Asia Pacific anticoagulant reversal drugs market, by country, 2018 - 2030 (USD Million)
  • Table 35. Asia Pacific anticoagulant reversal drugs market, by product type, 2018 - 2030 (USD Million)
  • Table 36. Asia Pacific anticoagulant reversal drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 37. Japan anticoagulant reversal drugs market, by product type, 2018 - 2030 (USD Million)
  • Table 38. Japan anticoagulant reversal drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 39. China anticoagulant reversal drugs market, by product type, 2018-2030 (USD Million)
  • Table 40. China anticoagulant reversal drugs market, by distribution channel, 2018-2030 (USD Million)
  • Table 41. India anticoagulant reversal drugs market, by product type, 2018 - 2030 (USD Million)
  • Table 42. India anticoagulant reversal drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 43. Australia anticoagulant reversal drugs market, by product type, 2018 - 2030 (USD Million)
  • Table 44. Australia anticoagulant reversal drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 45. South Korea anticoagulant reversal drugs market, by product type, 2018 - 2030 (USD Million)
  • Table 46. South Korea anticoagulant reversal drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 47. Thailand anticoagulant reversal drugs market, by product type, 2018 - 2030 (USD Million)
  • Table 48. Thailand anticoagulant reversal drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 49. Latin America anticoagulant reversal drugs market, by country, 2018 - 2030 (USD Million)
  • Table 50. Latin America anticoagulant reversal drugs market, by product type, 2018 - 2030 (USD Million)
  • Table 51. Latin America anticoagulant reversal drugs market, by distribution channel, 2018 - 2030 (USD Billion
  • Table 52. Brazil anticoagulant reversal drugs market, by product type, 2018 - 2030 (USD Million)
  • Table 53. Brazil anticoagulant reversal drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 54. Argentina anticoagulant reversal drugs market, by product type, 2018 - 2030 (USD Million)
  • Table 55. Argentina anticoagulant reversal drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 56. Middle East & Africa anticoagulant reversal drugs market, by country, 2018 - 2030 (USD Million)
  • Table 57. Middle East & Africa anticoagulant reversal drugs market, by product type, 2018 - 2030 (USD Million)
  • Table 58. Middle East & Africa anticoagulant reversal drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 59. South Africa anticoagulant reversal drugs market, by product type, 2018 - 2030 (USD Million)
  • Table 60. South Africa anticoagulant reversal drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 61. Saudi Arabia anticoagulant reversal drugs market, by product type, 2018 - 2030 (USD Million)
  • Table 62. Saudi Arabia anticoagulant reversal drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 63. UAE anticoagulant reversal drugs market, by product type, 2018 - 2030 (USD Million)
  • Table 64. UAE anticoagulant reversal drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 65. Kuwait anticoagulant reversal drugs market, by product type, 2018 - 2030 (USD Million)
  • Table 66. Kuwait anticoagulant reversal drugs market, by distribution channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Anticoagulant reversal drugs market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Product type outlook (USD Billion)
  • Fig. 10 Distribution channel outlook (USD Billion)
  • Fig. 11 Competitive landscape
  • Fig. 12 Anticoagulant reversal drugs market dynamics
  • Fig. 13 Anticoagulant reversal drugs market: Porter's five forces analysis
  • Fig. 14 Anticoagulant reversal drugs market: PESTLE analysis
  • Fig. 15 Anticoagulant reversal drugs market: Product type segment dashboard
  • Fig. 16 Anticoagulant reversal drugs market: Product type market share analysis, 2024 & 2030
  • Fig. 17 Prothrombin complex concentrates market, 2018 - 2030 (USD Million)
  • Fig. 18 Phytonadione (Vitamin K) market, 2018 - 2030 (USD Million)
  • Fig. 19 Andexanet alfa market, 2018 - 2030 (USD Million)
  • Fig. 20 Idarucizumab market, 2018 - 2030 (USD Million)
  • Fig. 21 Protamine market, 2018 - 2030 (USD Million)
  • Fig. 22 Others market, 2018 - 2030 (USD Million)
  • Fig. 23 Anticoagulant reversal drugs market: Distribution channel segment dashboard
  • Fig. 24 Anticoagulant reversal drugs market: Distribution channel market share analysis, 2024 & 2030
  • Fig. 25 Hospital pharmacy market, 2018 - 2030 (USD Million)
  • Fig. 26 Retail pharmacy market, 2018 - 2030 (USD Million)
  • Fig. 27 Online pharmacy market, 2018 - 2030 (USD Million)
  • Fig. 28 Anticoagulant reversal drugs market revenue, by region
  • Fig. 29 Regional marketplace: Key takeaways
  • Fig. 30 North America anticoagulant reversal drugs market, 2018 - 2030 (USD Million)
  • Fig. 31 U.S. country dynamics
  • Fig. 32 U.S. anticoagulant reversal drugs market, 2018 - 2030 (USD Million)
  • Fig. 33 Canada country dynamics
  • Fig. 34 Canada anticoagulant reversal drugs market, 2018 - 2030 (USD Million)
  • Fig. 35 Mexico country dynamics
  • Fig. 36 Mexico anticoagulant reversal drugs market, 2018 - 2030 (USD Million)
  • Fig. 37 Europe anticoagulant reversal drugs market, 2018 - 2030 (USD Million)
  • Fig. 38 UK country dynamics
  • Fig. 39 UK anticoagulant reversal drugs market, 2018 - 2030 (USD Million)
  • Fig. 40 Germany country dynamics
  • Fig. 41 Germany anticoagulant reversal drugs market, 2018 - 2030 (USD Million)
  • Fig. 42 France country dynamics
  • Fig. 43 France anticoagulant reversal drugs market, 2018 - 2030 (USD Million)
  • Fig. 44 Italy country dynamics
  • Fig. 45 Italy anticoagulant reversal drugs market, 2018 - 2030 (USD Million)
  • Fig. 46 Spain country dynamics
  • Fig. 47 Spain anticoagulant reversal drugs market, 2018 - 2030 (USD Million)
  • Fig. 48 Norway country dynamics
  • Fig. 49 Norway anticoagulant reversal drugs market, 2018 - 2030 (USD Million)
  • Fig. 50 Sweden country dynamics
  • Fig. 51 Sweden anticoagulant reversal drugs market, 2018 - 2030 (USD Million)
  • Fig. 52 Denmark country dynamics
  • Fig. 53 Denmark anticoagulant reversal drugs market, 2018 - 2030 (USD Million)
  • Fig. 54 Asia Pacific anticoagulant reversal drugs market, 2018 - 2030 (USD Million)
  • Fig. 55 Japan country dynamics
  • Fig. 56 Japan anticoagulant reversal drugs market, 2018 - 2030 (USD Million)
  • Fig. 57 China country dynamics
  • Fig. 58 China anticoagulant reversal drugs market, 2018 - 2030 (USD Million)
  • Fig. 59 India country dynamics
  • Fig. 60 India anticoagulant reversal drugs market, 2018 - 2030 (USD Million)
  • Fig. 61 Australia country dynamics
  • Fig. 62 Australia anticoagulant reversal drugs market, 2018 - 2030 (USD Million)
  • Fig. 63 South Korea country dynamics
  • Fig. 64 South Korea anticoagulant reversal drugs market, 2018 - 2030 (USD Million)
  • Fig. 65 Thailand country dynamics
  • Fig. 66 Thailand anticoagulant reversal drugs market, 2018 - 2030 (USD Million)
  • Fig. 67 Latin America anticoagulant reversal drugs market, 2018 - 2030 (USD Million)
  • Fig. 68 Brazil country dynamics
  • Fig. 69 Brazil anticoagulant reversal drugs market, 2018 - 2030 (USD Million)
  • Fig. 70 Argentina country dynamics
  • Fig. 71 Argentina anticoagulant reversal drugs market, 2018 - 2030 (USD Million)
  • Fig. 72 MEA anticoagulant reversal drugs market, 2018 - 2030 (USD Million)
  • Fig. 73 South Africa country dynamics
  • Fig. 74 South Africa anticoagulant reversal drugs market, 2018 - 2030 (USD Million)
  • Fig. 75 Saudi Arabia country dynamics
  • Fig. 76 Saudi Arabia anticoagulant reversal drugs market, 2018 - 2030 (USD Million)
  • Fig. 77 UAE country dynamics
  • Fig. 78 UAE anticoagulant reversal drugs market, 2018 - 2030 (USD Million)
  • Fig. 79 Kuwait country dynamics
  • Fig. 80 Kuwait anticoagulant reversal drugs market, 2018 - 2030 (USD Million)
  • Fig. 81 Company categorization
  • Fig. 82 Company market position analysis
  • Fig. 83 Strategic framework
目次
Product Code: GVR-4-68039-293-5

Anticoagulant Reversal Drugs Market Growth & Trends:

The global anticoagulant reversal drugs market size is expected to reach USD 2.78 billion by 2030, according to a new report by Grand View Research, Inc. It is expected to expand at a CAGR of 12.3% from 2025 to 2030. The rising number of bleeding disorders, the introduction of new drugs, and the growing number of cases requiring anticoagulant therapies are some of the factors anticipated to foster market growth during the forecast period.

In October 2015, Praxbind (idarucizumab) by Boehringer Ingelheim Pharmaceuticals was approved as an anticoagulant reversal drug indicated for patients treated with Pradaxa (dabigatran) during emergency surgery or uncontrolled or life-threatening bleeding. Hence, the availability of these anticoagulation reversal drugs allows doctors and patients to consider such treatment options with greater confidence, therefore boosting the demand for anticoagulant reversal drugs.

Bleeding disorders like hemophilia can be acquired or inherited. However, other bleeding disorders can occur from conditions, such as HIV, anemia, leukemia, cirrhosis of the liver, and vitamin K deficiency. According to the National Heart, Lung, and Blood Institute, more than 3 million people in the U.S. are affected with anemia, which is the most common blood disorder. The Leukemia & Lymphoma Society (LLS) stated that in the year 2020, the number of people expected to be diagnosed with leukemia is around 60,530. A rise in bleeding disorders is increasing the demand for anticoagulants, thus fueling the market growth.

However, the high cost of these reversal therapies is anticipated to restrain the market growth. As per the American College of Cardiology, 4-F PCC (Kcentra) helps in treating bleeding cases caused by rivaroxaban and apixaban and it is dosed at 50 units/kg. Its average wholesale price is USD 2.90 per unit, therefore treating a patient whose weight is 100 kg would cost around USD 14,500.

Anticoagulant Reversal Drugs Market Report Highlights:

  • The idarucizumab segment dominated the market, with a revenue share of 36.8% in 2024, driven by its high specificity for dabigatran as an effective option for reversing anticoagulation in emergencies.
  • Hospital pharmacies dominated the market with the largest revenue share of 48.6% in 2024, driven by the need for immediate access to anticoagulant reversal agents in emergencies.
  • North America anticoagulant reversal drugs market dominated the global market with a revenue share of 38.6% in 2024.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Product Type
    • 1.2.2. Distribution Channel
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Anticoagulant Reversal Drugs Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis

Chapter 4. Anticoagulant Reversal Drugs Market: Product Type Business Analysis

  • 4.1. Product Type Market Share, 2024 & 2030
  • 4.2. Product Type Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Product Type, 2018 to 2030 (USD Million)
  • 4.4. Prothrombin Complex Concentrates
    • 4.4.1. Prothrombin Complex Concentrates Market, 2018 - 2030 (USD Million)
  • 4.5. Phytonadione (Vitamin K)
    • 4.5.1. Phytonadione (Vitamin K) Market, 2018 - 2030 (USD Million)
  • 4.6. Andexanet Alfa
    • 4.6.1. Andexanet Alfa Market, 2018 - 2030 (USD Million)
  • 4.7. Idarucizumab
    • 4.7.1. Idarucizumab Market, 2018 - 2030 (USD Million)
  • 4.8. Protamine
    • 4.8.1. Protamine Market, 2018 - 2030 (USD Million)
  • 4.9. Others
    • 4.9.1. Others Market, 2018 - 2030 (USD Million)

Chapter 5. Anticoagulant Reversal Drugs Market: Distribution Channel Business Analysis

  • 5.1. Distribution Channel Market Share, 2024 & 2030
  • 5.2. Distribution Channel Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2018 to 2030 (USD Million)
  • 5.4. Hospital Pharmacy
    • 5.4.1. Hospital Pharmacy Market, 2018 - 2030 (USD Million)
  • 5.5. Retail Pharmacy
    • 5.5.1. Retail Pharmacy Market, 2018 - 2030 (USD Million)
  • 5.6. Online Pharmacy
    • 5.6.1. Online Pharmacy Market, 2018 - 2030 (USD Million)

Chapter 6. Anticoagulant Reversal Drugs Market: Regional Estimates & Trend Analysis by Product Type

  • 6.1. Regional Market Share Analysis, 2024 & 2030
  • 6.2. Regional Market Dashboard
  • 6.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 6.4. North America
    • 6.4.1. North America Anticoagulant Reversal Drugs Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Million)
    • 6.4.2. U.S.
      • 6.4.2.1. Key Country Dynamics
      • 6.4.2.2. Regulatory Framework
      • 6.4.2.3. Competitive Insights
      • 6.4.2.4. U.S. Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.3. Canada
      • 6.4.3.1. Key Country Dynamics
      • 6.4.3.2. Regulatory Framework
      • 6.4.3.3. Competitive Insights
      • 6.4.3.4. Canada Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.4. Mexico
      • 6.4.4.1. Key Country Dynamics
      • 6.4.4.2. Regulatory Framework
      • 6.4.4.3. Competitive Insights
      • 6.4.4.4. Mexico Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Europe
    • 6.5.1. Europe Anticoagulant Reversal Drugs Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Million)
    • 6.5.2. UK
      • 6.5.2.1. Key Country Dynamics
      • 6.5.2.2. Regulatory Framework
      • 6.5.2.3. Competitive Insights
      • 6.5.2.4. UK Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.3. Germany
      • 6.5.3.1. Key Country Dynamics
      • 6.5.3.2. Regulatory Framework
      • 6.5.3.3. Competitive Insights
      • 6.5.3.4. Germany Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.4. France
      • 6.5.4.1. Key Country Dynamics
      • 6.5.4.2. Regulatory Framework
      • 6.5.4.3. Competitive Insights
      • 6.5.4.4. France Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.5. Italy
      • 6.5.5.1. Key Country Dynamics
      • 6.5.5.2. Regulatory Framework
      • 6.5.5.3. Competitive Insights
      • 6.5.5.4. Italy Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.6. Spain
      • 6.5.6.1. Key Country Dynamics
      • 6.5.6.2. Regulatory Framework
      • 6.5.6.3. Competitive Insights
      • 6.5.6.4. Spain Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.7. Norway
      • 6.5.7.1. Key Country Dynamics
      • 6.5.7.2. Regulatory Framework
      • 6.5.7.3. Competitive Insights
      • 6.5.7.4. Norway Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.8. Denmark
      • 6.5.8.1. Key Country Dynamics
      • 6.5.8.2. Regulatory Framework
      • 6.5.8.3. Competitive Insights
      • 6.5.8.4. Denmark Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.9. Sweden
      • 6.5.9.1. Key Country Dynamics
      • 6.5.9.2. Regulatory Framework
      • 6.5.9.3. Competitive Insights
      • 6.5.9.4. Sweden Anticoagulant Reversal Drugs Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Million)
  • 6.6. Asia Pacific
    • 6.6.1. Asia Pacific Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.2. Japan
      • 6.6.2.1. Key Country Dynamics
      • 6.6.2.2. Regulatory Framework
      • 6.6.2.3. Competitive Insights
      • 6.6.2.4. Japan Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.3. China
      • 6.6.3.1. Key Country Dynamics
      • 6.6.3.2. Regulatory Framework
      • 6.6.3.3. Competitive Insights
      • 6.6.3.4. China Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.4. India
      • 6.6.4.1. Key Country Dynamics
      • 6.6.4.2. Regulatory Framework
      • 6.6.4.3. Competitive Insights
      • 6.6.4.4. India Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.5. South Korea
      • 6.6.5.1. Key Country Dynamics
      • 6.6.5.2. Regulatory Framework
      • 6.6.5.3. Competitive Insights
      • 6.6.5.4. South Korea Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.6. Australia
      • 6.6.6.1. Key Country Dynamics
      • 6.6.6.2. Regulatory Framework
      • 6.6.6.3. Competitive Insights
      • 6.6.6.4. Australia Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.7. Thailand
      • 6.6.7.1. Key Country Dynamics
      • 6.6.7.2. Regulatory Framework
      • 6.6.7.3. Competitive Insights
      • 6.6.7.4. Thailand Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.7. Latin America
    • 6.7.1. Latin America Anticoagulant Reversal Drugs Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Million)
    • 6.7.2. Brazil
      • 6.7.2.1. Key Country Dynamics
      • 6.7.2.2. Regulatory Framework
      • 6.7.2.3. Competitive Insights
      • 6.7.2.4. Brazil Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.7.3. Argentina
      • 6.7.3.1. Key Country Dynamics
      • 6.7.3.2. Regulatory Framework
      • 6.7.3.3. Competitive Insights
      • 6.7.3.4. Argentina Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.8. MEA
    • 6.8.1. MEA Anticoagulant Reversal Drugs Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Million)
    • 6.8.2. South Africa
      • 6.8.2.1. Key Country Dynamics
      • 6.8.2.2. Regulatory Framework
      • 6.8.2.3. Competitive Insights
      • 6.8.2.4. South Africa Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.8.3. Saudi Arabia
      • 6.8.3.1. Key Country Dynamics
      • 6.8.3.2. Regulatory Framework
      • 6.8.3.3. Competitive Insights
      • 6.8.3.4. Saudi Arabia Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.8.4. UAE
      • 6.8.4.1. Key Country Dynamics
      • 6.8.4.2. Regulatory Framework
      • 6.8.4.3. Competitive Insights
      • 6.8.4.4. UAE Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.8.5. Kuwait
      • 6.8.5.1. Key Country Dynamics
      • 6.8.5.2. Regulatory Framework
      • 6.8.5.3. Competitive Insights
      • 6.8.5.4. Kuwait Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Anticoagulant Reversal Drugs Market: Regional Estimates & Trend Analysis by Distribution Channel

  • 7.1. Regional Market Share Analysis, 2024 & 2030
  • 7.2. Regional Market Dashboard
  • 7.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 7.4. North America
    • 7.4.1. North America Anticoagulant Reversal Drugs Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Million)
    • 7.4.2. U.S.
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Regulatory Framework
      • 7.4.2.3. Competitive Insights
      • 7.4.2.4. U.S. Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.3. Canada
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Regulatory Framework
      • 7.4.3.3. Competitive Insights
      • 7.4.3.4. Canada Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.4. Mexico
      • 7.4.4.1. Key Country Dynamics
      • 7.4.4.2. Regulatory Framework
      • 7.4.4.3. Competitive Insights
      • 7.4.4.4. Mexico Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5. Europe
    • 7.5.1. Europe Anticoagulant Reversal Drugs Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Million)
    • 7.5.2. UK
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Regulatory Framework
      • 7.5.2.3. Competitive Insights
      • 7.5.2.4. UK Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.3. Germany
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Regulatory Framework
      • 7.5.3.3. Competitive Insights
      • 7.5.3.4. Germany Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.4. France
      • 7.5.4.1. Key Country Dynamics
      • 7.5.4.2. Regulatory Framework
      • 7.5.4.3. Competitive Insights
      • 7.5.4.4. France Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.5. Italy
      • 7.5.5.1. Key Country Dynamics
      • 7.5.5.2. Regulatory Framework
      • 7.5.5.3. Competitive Insights
      • 7.5.5.4. Italy Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.6. Spain
      • 7.5.6.1. Key Country Dynamics
      • 7.5.6.2. Regulatory Framework
      • 7.5.6.3. Competitive Insights
      • 7.5.6.4. Spain Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.7. Norway
      • 7.5.7.1. Key Country Dynamics
      • 7.5.7.2. Regulatory Framework
      • 7.5.7.3. Competitive Insights
      • 7.5.7.4. Norway Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.8. Denmark
      • 7.5.8.1. Key Country Dynamics
      • 7.5.8.2. Regulatory Framework
      • 7.5.8.3. Competitive Insights
      • 7.5.8.4. Denmark Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.9. Sweden
      • 7.5.9.1. Key Country Dynamics
      • 7.5.9.2. Regulatory Framework
      • 7.5.9.3. Competitive Insights
      • 7.5.9.4. Sweden Anticoagulant Reversal Drugs Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Million)
  • 7.6. Asia Pacific
    • 7.6.1. Asia Pacific Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.2. Japan
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Regulatory Framework
      • 7.6.2.3. Competitive Insights
      • 7.6.2.4. Japan Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.3. China
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Regulatory Framework
      • 7.6.3.3. Competitive Insights
      • 7.6.3.4. China Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.4. India
      • 7.6.4.1. Key Country Dynamics
      • 7.6.4.2. Regulatory Framework
      • 7.6.4.3. Competitive Insights
      • 7.6.4.4. India Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.5. South Korea
      • 7.6.5.1. Key Country Dynamics
      • 7.6.5.2. Regulatory Framework
      • 7.6.5.3. Competitive Insights
      • 7.6.5.4. South Korea Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.6. Australia
      • 7.6.6.1. Key Country Dynamics
      • 7.6.6.2. Regulatory Framework
      • 7.6.6.3. Competitive Insights
      • 7.6.6.4. Australia Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.7. Thailand
      • 7.6.7.1. Key Country Dynamics
      • 7.6.7.2. Regulatory Framework
      • 7.6.7.3. Competitive Insights
      • 7.6.7.4. Thailand Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.7. Latin America
    • 7.7.1. Latin America Anticoagulant Reversal Drugs Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Million)
    • 7.7.2. Brazil
      • 7.7.2.1. Key Country Dynamics
      • 7.7.2.2. Regulatory Framework
      • 7.7.2.3. Competitive Insights
      • 7.7.2.4. Brazil Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.7.3. Argentina
      • 7.7.3.1. Key Country Dynamics
      • 7.7.3.2. Regulatory Framework
      • 7.7.3.3. Competitive Insights
      • 7.7.3.4. Argentina Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.8. MEA
    • 7.8.1. MEA Anticoagulant Reversal Drugs Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Million)
    • 7.8.2. South Africa
      • 7.8.2.1. Key Country Dynamics
      • 7.8.2.2. Regulatory Framework
      • 7.8.2.3. Competitive Insights
      • 7.8.2.4. South Africa Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.8.3. Saudi Arabia
      • 7.8.3.1. Key Country Dynamics
      • 7.8.3.2. Regulatory Framework
      • 7.8.3.3. Competitive Insights
      • 7.8.3.4. Saudi Arabia Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.8.4. UAE
      • 7.8.4.1. Key Country Dynamics
      • 7.8.4.2. Regulatory Framework
      • 7.8.4.3. Competitive Insights
      • 7.8.4.4. UAE Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.8.5. Kuwait
      • 7.8.5.1. Key Country Dynamics
      • 7.8.5.2. Regulatory Framework
      • 7.8.5.3. Competitive Insights
      • 7.8.5.4. Kuwait Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Participant Overview
  • 8.2. Company Market Position Analysis
  • 8.3. Company Categorization
  • 8.4. Strategy Mapping
  • 8.5. Company Profiles/Listing
    • 8.5.1. Pfizer Inc
      • 8.5.1.1. Overview
      • 8.5.1.2. Financial Performance
      • 8.5.1.3. Product Benchmarking
      • 8.5.1.4. Strategic Initiatives
    • 8.5.2. AstraZeneca
      • 8.5.2.1. Overview
      • 8.5.2.2. Financial Performance
      • 8.5.2.3. Product Benchmarking
      • 8.5.2.4. Strategic Initiatives
    • 8.5.3. Dr. Reddy's Laboratories Ltd
      • 8.5.3.1. Overview
      • 8.5.3.2. Financial Performance
      • 8.5.3.3. Product Benchmarking
      • 8.5.3.4. Strategic Initiatives
    • 8.5.4. Endo International plc
      • 8.5.4.1. Overview
      • 8.5.4.2. Financial Performance
      • 8.5.4.3. Product Benchmarking
      • 8.5.4.4. Strategic Initiatives
    • 8.5.5. Teva Pharmaceutical Industries Ltd
      • 8.5.5.1. Overview
      • 8.5.5.2. Financial Performance
      • 8.5.5.3. Product Benchmarking
      • 8.5.5.4. Strategic Initiatives
    • 8.5.6. Sun Pharmaceutical Industries Ltd
      • 8.5.6.1. Overview
      • 8.5.6.2. Financial Performance
      • 8.5.6.3. Product Benchmarking
      • 8.5.6.4. Strategic Initiatives
    • 8.5.7. Mylan N.V.
      • 8.5.7.1. Overview
      • 8.5.7.2. Financial Performance
      • 8.5.7.3. Product Benchmarking
      • 8.5.7.4. Strategic Initiatives
    • 8.5.8. Novartis AG.
      • 8.5.8.1. Overview
      • 8.5.8.2. Financial Performance
      • 8.5.8.3. Product Benchmarking
      • 8.5.8.4. Strategic Initiatives
    • 8.5.9. Lupin
      • 8.5.9.1. Overview
      • 8.5.9.2. Financial Performance
      • 8.5.9.3. Product Benchmarking
      • 8.5.9.4. Strategic Initiatives
    • 8.5.10. Cipla Inc
      • 8.5.10.1. Overview
      • 8.5.10.2. Financial Performance
      • 8.5.10.3. Product Benchmarking
      • 8.5.10.4. Strategic Initiatives